Covance Solution Bridges Preclinical to Clinical Development
Covance Inc., the world’s most comprehensive drug development company, today announced the introduction of Covance Early Phase Development Solutions,
Covance has introduced its Early Phase Development Solutions, a multi-disciplined approach to early drug development that provides sponsors access to a molecule solution team made up of experts from nonclinical, clinical and regulatory disciplines. These experts will focus on the sponsor’s unique target product profile to provide ongoing continuity in strategic program design that spans nonclinical through to first-in-human ready, Phase II ready, proof-of-concept and full-development ready.
Read the full text here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
